Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

992.58 +5.31 (+0.54%)
Streaming Delayed Price Updated: 11:55 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,... 
Via Benzinga
Exposures Fossil Fuels
10 Biggest Price Target Changes For Wednesday
Morgan Stanley boosted the price target on Adobe Inc. (NASDAQ: 
Via Benzinga
After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related... 
Via Benzinga
Exposures COVID-19
U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy
The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Read Next: ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
Tuesday Talk: Up But Under 4500
Both the S&P 500 and the Dow closed higher on Monday to end their five day losing streak, while the Nasdaq closed slightly lower than it's Friday close. Closing at 4,469 the S&P 500 was up 10 points... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Portfolio Highlights: Quarterly Movers & Shakers, September 2021
During the past three months, the S&P 500 index increased 7.3% thanks to the strong economic recovery from the pandemic. All the following high-quality stocks generated strong double-digit gains during... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema. 
Via The Motley Fool
Analyst Ratings For Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observ... 
Via Benzinga
3 Hot Stocks to Buy in September
In the stock market, what goes up doesn't have to come down. 
Via The Motley Fool
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
Now May Be the Big Moment for These 2 COVID Stocks
Their products are seeing a surge in demand. 
Via The Motley Fool
Exposures COVID-19
5 Stocks That Powered S&P 500 ETF in August
The S&P 500 hit a series of record highs in August despite bouts of volatility and uncertainty. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential
Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron... 
Via Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary... 
Via Benzinga
Regeneron Pharmaceuticals Is My Value Stock Of The Week
Regeneron Pharmaceuticals, Inc. has become popular over the past year due to its COVID 19 cocktail treatment. It has more than a couple blockbuster drugs, with even more on the way. The best part is... 
Via Talk Markets
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Market Briefing For Thursday, Aug. 26
Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine,... 
Via Talk Markets
5 Stocks At the Forefront of the Latest S&P 500 Rally
Here are five stocks in the S&P 500 that led the market higher amid the uncertainty. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related... 
Via Benzinga
Return on Capital Employed Insights for Regeneron Pharmaceuticals
After pulling data from Benzinga Pro it seems like during Q2, Regeneron Pharmaceuticals (NASDAQ:REGN) earned $3.35 billion, a 200.82% increase from the preceding quarter.... 
Via Benzinga
Tesla And The Quest For Alpha
Tesla exemplifies both the successes and failures of our security selection method. How it works and where we go from here. 
Via Talk Markets
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
Market Briefing For Monday, Aug. 23
We might be near a moment of truth for the Senior Indexes, either in just a few days or postponed until after Labor Day. 
Via Talk Markets
Regeneron Pharmaceutical Stock Earns 84 Relative Strength Rating
A Relative Strength Rating upgrade for Regeneron Pharmaceutical shows improving technical performance. 
Via Investor's Business Daily
Exposures COVID-19
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.